TINN2: Treat Infection in NeoNates 2 (TINN2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02282176|
Recruitment Status : Withdrawn
First Posted : November 4, 2014
Last Update Posted : February 25, 2016
|Condition or disease||Intervention/treatment||Phase|
|Bronchopulmonary Dysplasia||Drug: Azithromycin Drug: Placebo||Phase 3|
In contrast to the situation in adults, most medicines used to treat the children of Europe have not been tested and are not authorised for use in children. In particular, 46% medicines prescribed to children in hospital are either unlicensed for their age group or, if licensed, are prescribed off label. Of the children who receive at least one medication in hospital, 67% receive an unlicensed or off-label drug, and in the context of intensive care, this rises to up to 90% of patients.
The new Paediatric Regulation entered into force in early 2007 ensure that medicines for use in children are of high quality, ethically evaluated and authorised appropriately. The Paediatric-Use Marketing Authorisation (PUMA) is a new type of marketing authorisation for drugs not covered by a patent, already available on the market for adults. PUMA applies to medicines lacking information and/or appropriate formulation for children of all ages.
Thus, the European Medicines Agency (EMA) has published a list of drugs, which azithromycin belongs, as priority medicinal products needing an evaluation in the paediatric population.
Bronchopulmonary dysplasia (BPD) is a specific disease of prematurity accompanied by pulmonary inflammation. Multiple factors may contribute to the occurrence of BPD. In infants who are at risk of developing CLD, one frequent finding is colonisation of the preterm lung with the microbe Ureaplasma.
Two Meta-Analyses and recent studies have suggested an association between the presence of pulmonary Ureaplasma and the development of BPD.
Azithromycin is a macrolide antibiotic active against Ureaplasma spp with anti-inflammatory properties. Thus, it may be effective in reducing the severity of bronchopulmonary diseases in which both infection and inflammation play a role.
TINN2 project: the aim of the TINN2 study is to evaluate the efficacy of azithromycin in prevention of bronchopulmonary dysplasia in preterm neonates. TINN2 is a consortium involving European leaders in neonatology, paediatric pharmacology, methodology and several SMEs that will establish links with ethical bodies and regulatory authorities.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Preterm Infants|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||January 2017|
|Estimated Study Completion Date :||January 2018|
10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
Azithromycin IV 10mg/kg daily for 10 days
Placebo Comparator: Placebo
Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
Azithromycin placebo (5% Dextrose) daily for 10 days
Other Name: 5% Dextrose
- The proportion of surviving infants without CLD (Chronic Lung Disease) in the azithromycin treatment group when compared to placebo at 36 weeks post-menstrual age. [ Time Frame: 36 weeks post-menstrual age ]
- Mortality rate (at 28 days, 36 weeks PMA, 2 years) [ Time Frame: 28 days, 36 weeks PMA, 2 years ]
- Severity of CLD (Chronic Lung Disease) according to NIH definition [ Time Frame: 36 weeks PMA ]
- Microbiology assessment [ Time Frame: Baseline and days 5, 10, 21 ]
Microbiology assessment at baseline and days 5, 10, 21:
Pulmonary colonisation by Ureaplasma spp. and Mycoplasma spp. (respiratory culture of endotracheal/nasopharyngeal aspirates and nasogastric aspirates (nasogastric only for Ureaplasma spp. at baseline) and species-specific quantitative PCR)
- Inflammation Markers [ Time Frame: Baseline and days 5, 10, 21 ]
Subroup of patients:
Inflammatory markers at baseline and days 5, 10, 21 in plasma and bronchoalveolar lavage
Identification of the following: IL-1, IL-6, IL-8, TNF-a, MCP-1, PMN/Am/TCC, C5a.
- Duration of positive pressure respiratory support (i.e. conventional mechanical ventilation, nasal ventilation, continuous positive airway pressure, CPAP) and supplemental oxygen [ Time Frame: up to 36 weeks PMA ]
- Emergence of resistance to azithromycin in Ureaplasma spp. isolated from endotracheal or nasopharyngeal samples at baseline, days 5, 10 and 21 [ Time Frame: Baseline, days 5, 10 and 21 ]On each positive PCR a culture will be performed. Then, an antibiotic susceptibility testing upon positive cultures
- Resistance to azithromycin among microbes isolated from stool or rectal swab obtained at baseline and day 21 [ Time Frame: Baseline and day 21 ]Antibiotic susceptibility testing on any identified microbes
- Plasma concentrations [ Time Frame: days 1, 3, 6 as required ]
Each patients to be allocated two sample timepoints from the following schedule:
1 sample within 5 min after the end of dose administration (day 1) Or 1 sample at 6 hours after start of infusion (day 1) Or 1 sample at 12 hours after start of infusion (day 1)
1 sample at 48 hours - just prior to the third administration (day 3) Or 1 sample at 144 hours- just prior to the sixth administration (day 6)
- Exposure to antibiotics other than azithromycin during the hospital stay [ Time Frame: up to 36weeks PMA ]
- Development of complications of prematurity [ Time Frame: 24 months ]Development of complications of prematurity: Nosocomial infection (sepsis, meningitis, pneumonia); intraventricular haemorrhage; necrotising enterocolitis; retinopathy of prematurity; patent ductus arteriosus; pulmonary hemorrhage, pneumothorax and pulmonary interstitial emphysema during hospital stay
- Number of Adverse Events [ Time Frame: 24 months ]
- Number of participants with dysrhythmic episodes and QTc interval [ Time Frame: 24 months ]
- C-Reactive Protein [ Time Frame: 24 months ]
- Neurodevelopmental assessment: Assessment of neurodevelopment using the 3rd edition of the Bayley Scales of Infant Development at the corrected age of 24 months [ Time Frame: 24 months ]Long-term follow up at the corrected age of 24 months
- Respiratory function assessment: Assessment of respiratory symptoms using a validated International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire [ Time Frame: 24 months ]Long-term follow up at the corrected age of 24 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02282176
|Centre Hospitalier Chrétien (CHC)|
|Assistance Publique Hôpitaux de Paris (APHP)|
|Institut National de la Santé et de la Recherche Médicale (INSERM)|
|Only for children pharmaceuticals (04CP)|
|Heinrich-Heine-Universität Düsseldorf (UDUS)|
|University of Ulm (UUlm)|
|Semmelweis University Budapest, Faculty of Medicine (SOTE)|
|Pandy Kalman County Hospital|
|Mario Negri Institute (IRFMN)|
|Advanced Biological Laboratories ABL (ABL SA)|
|Erasmus-University Medical Center (ERAMUS)|
|Karolinska Institutet (KI)|
|Cardiff University (CU)|
|Cardiff, United Kingdom|
|University of Liverpool (UOL)|
|Liverpool, United Kingdom|
|Simcyp Limited (SimCyp)|
|Sheffield, United Kingdom|
|Principal Investigator:||Sailesh Kotecha||Cardiff University|